Liminal BioSciences Inc. (LMNL)
| Market Cap | 74.86M |
| Revenue (ttm) | 1.54M |
| Net Income (ttm) | -94.68M |
| Shares Out | 29.94M |
| EPS (ttm) | -3.24 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 80,460 |
| Open | 2.55 |
| Previous Close | 2.58 |
| Day's Range | 2.47 - 2.60 |
| 52-Week Range | 2.13 - 11.99 |
| Beta | 1.41 |
| Analysts | Buy |
| Price Target | 13.29 (+431.4%) |
| Est. Earnings Date | Nov 11, 2021 |
About LMNL
Liminal BioSciences Inc., a clinical-stage biopharmaceutical company, focuses on discovery, development, and commercialization of novel small molecule drug candidates for the treatment of patients suffering from respiratory fibrotic diseases and other fibrotic or inflammatory diseases that have high unmet medical needs. It operates through two segments, Small Molecule Therapeutics and Plasma-Derived Therapeutics. The Small Molecule Therapeutics segment's lead product candidate is fezagepras (PBI-4050), which is in Phase 1 for the treatment of i...
Financial Performance
In 2020, LMNL's revenue was 3.32 million, a decrease of -32.36% compared to the previous year's 4.90 million. Losses were -119.59 million, -42.45% less than in 2019.
Financial numbers in millions CADFinancial StatementsAnalyst Forecast
According to 2 analysts, the average rating for LMNL stock is "Buy." The 12-month stock price forecast is 13.29, which is an increase of 431.42% from the latest price.
News
After Plunging 34.5% in 4 Weeks, Here's Why the Trend Might Reverse for Liminal BioSciences Inc. (LMNL)
Liminal BioSciences Inc. (LMNL) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earni...
Liminal BioSciences Inc. (LMNL) Reports Q2 Loss, Misses Revenue Estimates
Liminal BioSciences Inc. (LMNL) delivered earnings and revenue surprises of 22.73% and -90.24%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?
Liminal BioSciences Reports Second Quarter 2021 Financial Results
Receipt of FDA Approval for Ryplazim® (plasminogen, human-tvmh) Receipt of a Rare Pediatric Disease Priority Review Voucher Signature of Agreement to Divest Plasma-Derived Therapeutics Business to Kedri...
Liminal BioSciences Stock Is Trading Higher On Sale Of Priority Review Voucher For $105M
Liminal BioSciences Inc's (NASDAQ: LMNL) subsidiary Prometic Biotherapeutics Inc has agreed to sell its Rare Pediatric Disease Priority Review Voucher (PRV) for $105M. The FDA granted the PRV with the a...
Liminal BioSciences Announces Sale of Priority Review Voucher for USD105M
LAVAL, QC and CAMBRIDGE, England , Aug. 9, 2021 /PRNewswire/ - Liminal BioSciences Inc. (Nasdaq: LMNL) ("Liminal BioSciences" or the "Company"), announced today that, its subsidiary Prometic Biotherapeu...
Liminal BioSciences Inc. (LMNL) May Report Negative Earnings: Know the Trend Ahead of Q2 Release
Liminal BioSciences Inc. (LMNL) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Liminal BioSciences Announces Closing of Sale of Plasma-Derived Therapeutics Manufacturing Facility
LAVAL, QC and CAMBRIDGE, England, July 9, 2021 /PRNewswire/ - Liminal BioSciences Inc. (Nasdaq: LMNL) ("Liminal BioSciences" or the "Company"), a clinical-stage biopharmaceutical company, announced toda...
Liminal BioSciences Announces Signature of a Share Purchase Agreement for sale of Remaining Plasma-derived Business w...
LAVAL, QC and CAMBRIDGE, England, June 23, 2021 /PRNewswire/ - Liminal BioSciences Inc. (Nasdaq: LMNL) ("Liminal BioSciences" or the "Company"), announced today that, Kedrion S.p.A ("Kedrion") has exerc...
Liminal Announces Voting Results of Its 2021 Annual and Special General Meeting of Shareholders (AGM)
LAVAL, QC and CAMBRIDGE, England, June 4, 2021 /PRNewswire/ - Liminal BioSciences Inc. (Nasdaq: LMNL) ("Liminal BioSciences" or the "Company") announced the voting results from its Annual General and Sp...
Liminal BioSciences Announces FDA Approval for its Biologics License Application for Ryplazim® (plasminogen, human-tvmh)
LAVAL, QC and CAMBRIDGE, England, June 4, 2021 /PRNewswire/ - Liminal BioSciences Inc. (Nasdaq: LMNL) ("Liminal BioSciences" or the "Company") announced today that the U.S. Food & Drug Administration (F...
Liminal BioSciences Stock Falls on Scrapping Further Development of Fezagepras
Based on interim pharmacokinetics (PK) results from the ongoing multiple ascending dose study Liminal BioSciences Inc (NASDAQ: LMNL) has decided not to move fezagepras into a Phase 2 study in Idiopathic...
Liminal BioSciences Provides an Update on Currently Planned Clinical Activities for Fezagepras
LAVAL, QC and CAMBRIDGE, England, May 28, 2021 /PRNewswire/ - Liminal BioSciences Inc. (Nasdaq: LMNL) ("Liminal BioSciences" or the "Company"), a clinical-stage biopharmaceutical company, announced toda...
Liminal BioSciences Announces Closing of Divestiture of Plasma Collection Centers and Enters into Option Agreement wi...
LAVAL, QC and CAMBRIDGE, England, May 21, 2021 /PRNewswire/ - Liminal BioSciences Inc. (Nasdaq: LMNL) ("Liminal BioSciences" or the "Company"), a clinical-stage biopharmaceutical company, announced toda...
Liminal BioSciences Reports First Quarter 2021 Financial Results
Updated Business Strategy Focused on Small Molecule Therapeutics Kedrion to acquire, for a total of USD 17M, 2 plasma collection centers and an option to acquire the remaining plasma-derived therapeutic...
Liminal BioSciences To Offload Plasma Collection and Plasma-Derived Therapeutics Business To Kedrion
Liminal BioSciences Inc (NASDAQ: LMNL) has agreed to sell its plasma collection and plasma-derived therapeutics business to Kedrion S.P.A. Under the Share Purchase Agreement, Liminal will enter into an ...
Liminal BioSciences Enters into Agreement with Kedrion to Divest Its Plasma Collection and Plasma-Derived Therapeutic...
Kedrion to acquire, for a total of USD 17M, 2 plasma collection centers and an option to acquire the remaining plasma-derived therapeutic business for USD 5M Liminal to receive up to 70% of net proceeds...
Liminal BioSciences Inc. (LMNL) May Report Negative Earnings: Know the Trend Ahead of Q1 Release
Liminal BioSciences Inc. (LMNL) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Liminal BioSciences Inc. (LMNL) Reports Q4 Loss, Tops Revenue Estimates
Liminal BioSciences Inc. (LMNL) delivered earnings and revenue surprises of -8.77% and 52.73%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?
Liminal BioSciences Reports Fourth Quarter and Year End 2020 Financial Results
Initiated Phase 1 Multiple Ascending Dose Clinical Trial of Fezagepras OXER1 Antagonist Preclinical R&D Program Acquired Changes to Board of Directors & Executive Team US$30M in gross proceeds from a pr...
Liminal BioSciences Inc. (LMNL) May Report Negative Earnings: Know the Trend Ahead of Q4 Release
Liminal BioSciences Inc. (LMNL) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Liminal BioSciences Announces First Subject Dosed in Phase 1 Multiple Ascending Dose Clinical Trial of Fezagepras
LAVAL, QC, and CAMBRIDGE, England, Dec. 15, 2020 /PRNewswire/ - Liminal BioSciences Inc. (Nasdaq: LMNL) ("Liminal BioSciences" or the "Company"), a clinical-stage biopharmaceutical company, today announ...
Liminal BioSciences Inc. (LMNL) CEO Bruce Pritchard on Q3 2020 Results - Earnings Call Transcript
Liminal BioSciences Inc. (LMNL) CEO Bruce Pritchard on Q3 2020 Results - Earnings Call Transcript
Liminal Biosciences to Present at The Stifel Virtual Healthcare Conference
LAVAL, QC and CAMBRIDGE, England, Nov. 13, 2020 /PRNewswire/ - Liminal BioSciences Inc. (Nasdaq: LMNL) ("Liminal BioSciences" or the "Company"), a clinical-stage biopharmaceutical company, announced tha...
Liminal Biosciences to Reschedule Reporting of Q3 2020 Results and Conference Call
LAVAL, QC and CAMBRIDGE, England, Nov. 10, 2020 /PRNewswire/ - Liminal BioSciences Inc. (Nasdaq: LMNL) ("Liminal BioSciences" or the "Company"), a clinical-stage biopharmaceutical company, today announc...